Premenstrual syndrome (PMS) is medical condition involving emotional, physical, psychological, and mood disturbances that occur after a woman's ovulation, and typically ends with the onset of her menstrual flow. The most common mood-related symptoms involved in premenstrual syndrome are irritability, depression, crying, oversensitivity, and mood swings. The most common physical symptoms involved in premenstrual syndrome are fatigue, bloating, breast tenderness (mastalgia), acne, and appetite changes with food cravings. One of the advanced and more severe form of PMS is premenstrual dysphoric disorder (PMDD) also known as late luteal phase dysphoric disorder, occurs in a smaller number of women and leads to significant loss of function because of unusually severe symptoms. Globally increasing registered cases of PMS due to life style related issues and increasing awareness amongst women in the developed nations is expected to drive the demand for PMS however regulations over the usage of such medicines in some of the nations and higher R&D cost involved to develop new drugs and treatments is expected to be the key constraints market during the period of study.
This report identifies the global premenstrual syndrome treatment market
size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to premenstrual syndrome treatment market.
Geographically, North America dominated the premenstrual syndrome treatment market due to higher awareness about such diseases, higher registered cases due to life style related health issues and well developed healthcare infrastructure. North America was followed by Europe and Asia-Pacific as the second and third largest consumer of premenstrual syndrome treatment. Asia Pacific is projected to have the fastest growth, owing to rapidly expanding healthcare infrastructure, increasing awareness especially in the major regional economies such as India and China in the region.
This report segments premenstrual syndrome treatment market on the basis of treatment type and regional market as follows:
This report identifies all the major companies operating in the premenstrual syndrome treatment market. Some of the major companies’ profiles in detail are as follows:
- On the basis of treatment type this report on premenstrual syndrome treatment market is segmented as follows, covering major segments as follows: Painkillers, Oral contraceptive pills, Estrogen-only patches and implants, Gonadotropin-releasing hormone (GnRH) analogues, Selective serotonin reuptake inhibitors (SSRIs)
- This report on premenstrual syndrome treatment has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region
- Pherin Pharmaceuticals, Inc.
- DEKK-TEC, Inc.
- Umecrine Mood AB
- MetP Pharma AG
- Bristol Meyer Squibb